Needham Raises PT On Cubist Pharmaceuticals To $33

by Benzinga Staff
April 5, 2011 8:17 AM | 9 seconds read

MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO

As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off.  Claim your 50% discount here.

Needham has raised the price target on Cubist Pharmaceuticals (NASDAQ: CBST) from $27 to $33 and following the company's settlement with Teva (NASDAQ: TEVA). Buy rating maintained.

MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO

As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off.  Claim your 50% discount here.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Price TargetAnalyst RatingsBiotechnologycubist pharmaceuticalsHealth CareNeedhamPharmaceuticalsTEVA PHARMACEUTICALS

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.